The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Purpose
This guidance is to assist manufacturers and sponsors to understand the requirements for compliance with the new quality standards for MDMA and psilocybine active pharmaceutical ingredient (API) and finished product.